Asonor’s clinical evidence includes historical clinical investigations and information collected during routine use. This page explains the different types of evidence, what they can tell you and the limits of the conclusions.

This summary is prepared by TannerMedico A/S, the manufacturer of Asonor. It is manufacturer information, not an independent product ranking or a head-to-head comparison with competing sprays.

Start with the intended use

Asonor is intended to reduce snoring through local lubrication and softening of the mucous membranes in the throat. The solution is applied through the nostrils so that it reaches the throat. Consult the current instructions for use for the full intended purpose, application and precautions.

Historical clinical investigations

The manufacturer’s clinical evaluation describes two historical studies sponsored by TannerMedico. Both involved men aged 50–65 who snored every night. The findings should be read with those populations and study designs in mind.

An open acceptance study: 218 participants

Participants used Asonor over six months and completed questionnaires with their bed partners. The clinical evaluation reports improvements in participant- and partner-reported snoring during use.

This was an open study without a blinded comparison group. Reported improvement and continued product use are different outcomes. The study cannot, on its own, establish how much of a reported change was caused by the product or predict an individual user’s result.

A double-blind controlled study: 50 participants

This study compared Asonor with a solution containing the same ingredients except polysorbate 80. The clinical evaluation reports improvements from baseline in both treatment periods, but no statistically significant difference between the periods in the questionnaire results. It also reports no difference in respiratory or laryngeal sound measurements between the comparison and test periods.

These findings should not be presented as proof that polysorbate 80 alone accounts for the effect, or as proof that Asonor outperformed an inactive placebo. The clinical evaluation also notes uncertainty about the treatment sequence. The comparison solution contained other formulation ingredients.

What about user feedback?

Historical user panels, follow-up questionnaires and post-purchase feedback can provide information about experience during use. They are not interchangeable with a controlled clinical study. Who responded, how the question was asked, the observation period and the definition of improvement all affect how a result should be interpreted.

For this reason, a satisfaction percentage should not be read as a guaranteed success rate for everyone who buys Asonor. We do not combine different study types into a single success percentage on this page.

Safety information and limitations

The open study recorded symptoms including dryness and irritation of the nose or throat. Recording a symptom does not by itself establish that the product caused it. Equally, a report of no serious adverse events is not a promise that unwanted effects are impossible.

Read the current product instructions and precautions. Contact a healthcare professional about symptoms that concern you, and contact TannerMedico about a suspected product incident.

Snoring and sleep apnea are different questions

Less audible snoring does not establish that breathing is normal throughout the night. Breathing pauses, gasping or choking during sleep, or persistent daytime sleepiness warrant medical advice. Do not use a product trial to postpone assessment or change prescribed sleep-apnea treatment.

Sources and product information

  • Manufacturer-held clinical investigation, 1989: an acceptance study and a double-blind controlled study. Unpublished; described in TannerMedico’s clinical evaluation.
  • Historical manufacturer-held post-market follow-up and user-feedback records. These are supportive sources with different methods and limitations.
  • Asonor: instructions for use
  • Asonor: product information
  • NHS: sleep apnoea

For questions about the evidence or access to available product documentation, contact the Asonor team. This page provides general information and does not replace individual medical advice.